Immune Checkpoint Inhibitors and Myasthenic Syndromes: A Case Report of a Metastatic Renal Cell Carcinoma Patient Treated With Nivolumab

J Clin Neuromuscul Dis. 2018 Dec;20(2):99-100. doi: 10.1097/CND.0000000000000220.

Authors

Alessio Cortellini^{1

2}, Luca Napoleoni^{1

2}, Nicola Cimini³, Alessandro Parisi^{1

2}, Francesco Pavese^{1

2}, Carla DʼOrazio^{1

2}, Lucilla Verna², Giampiero Porzio^{1

2}, Corrado Ficorella^{1

2}

Affiliations

¹ Medical Oncology Unit, St. Salvatore Hospital, University of L'Aquila, L'Aquila, Italy.
² Department of Biotechnological and Applied Clinical Sciences, University of L'Aquila, L'Aquila, Italy.
³ Department of Neurophysiopathology, St. Salvatore Hospital L'Aquila, L'Aquila, Italy.

PMID: 30439756
DOI: 10.1097/CND.0000000000000220

No abstract available

Publication types

Case Reports

MeSH terms

Aged
Antineoplastic Agents, Immunological / adverse effects*
Carcinoma, Renal Cell / drug therapy*
Female
Humans
Myasthenia Gravis / chemically induced*
Nivolumab / adverse effects*

Substances

Antineoplastic Agents, Immunological
Nivolumab